Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors by Devreux, Vincent et al.
 
 
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for all 
UGent research publications. Ghent University has implemented a mandate stipulating that all 
academic publications of UGent researchers should be deposited and archived in this repository. 
Except for items where current copyright restrictions apply, these papers are available in Open 
Access. 
 
This item is the archived peer‐reviewed author‐version of: 
Title:  
Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium 
falciparum growth inhibitors 
Author(s):  Vincent Devreux, J Wiesner, Jan Goeman, Johan Van der Eycken, H Jomaa and Serge Van 
Calenbergh  
Source: JOURNAL OF MEDICINAL CHEMISTRY (2006), 49(8), 2656-2660, DOI: 
10.1021/jm051177c 
 
 1
Synthesis and Biological Evaluation of Cyclopropyl 
Analogues of Fosmidomycin as Potent P. falciparum 
Growth Inhibitors 
Vincent Devreux,#, Jochen Wiesner,$ Jan L. Goeman, Johan Van der Eycken, Hassan Jomaa$ and 
Serge Van Calenbergh#,* 
# Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, 
Harelbekestraat 72, B-9000 Gent, Belgium,  
 Laboratory of Organic and Bioorganic Chemistry, Department of Organic Chemistry, Faculty of 
Sciences, Ghent University, Krijgslaan 281 (S.4), B-9000 Gent, Belgium, and 
$ Universitätsklinkum Giessen und Marburg, Institut für Klinische Chemie und Pathobiochemie, 
Gaffkystrasse 11, 35392 Giessen, Germany. 
 
* To whom correspondence should be addressed. Phone: +32 9 264 81 24. Fax + 32 9 264 81 46. E-
MAIL: Serge.VanCalenbergh@UGent.be. 
RECEIVED DATE (to be automatically inserted after your manuscript is accepted if required 
according to the journal that you are submitting your paper to) 
ABSTRACT A series of fosmidomycin analogues featuring restricted conformational mobility has been 
synthesized and evaluated as inhibitors of 1-deoxy-D-xylulose-5-phosphate (DOXP) reductoisomerase 
and as growth inhibitors of P. falciparum. The enantiomerically pure trans cyclopropyl N-acetyl 
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analogue 3b showed comparable inhibitory activity as fosmidomycin toward E. coli DOXP 
reductoisomerase and proved equally active when tested in vitro for P. falciparum growth inhibition. 
Conversely, the -phenyl cis-cyclopropyl analogue 4 showed virtually no inhibition of the enzyme.  
KEYWORDS: FOSMIDOMYCIN, CYCLOPROPYL PHOSPHONATE, CONFORMATIONAL 
RESTRICTION, 2C-METHYL-D-ERITHRYTOL 4-PHOSPHATE PHOSPHATE PATHWAY, 1-
DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE 
MANUSCRIPT TEXT  
Malaria is fatal for approximately 1.5 to 2.7 million people each year. Among other reasons, the 
increasing resistance to prevalent drugs such as chloroquine allows for a widespread emergence of 
Plasmodium falciparum, the causative agent of malaria tropica. 
The discovery of the 2C-methyl-D-erithrytol 4-phosphate phosphate (MEP) pathway as a mevalonate-
independent pathway for the biosynthesis of isoprenoids fueled research activities dealing with the 
characterization of the enzymes involved in this pathway and the search for inhibitors of these novel 
targets.1,2 This MEP pathway is of particular interest since it is present in most bacteria, plants and the 
malaria parasite P. falciparum, but is absent in humans.  
The natural antibiotics fosmidomycin (1) and FR-900098 (2) (Figure 1) posses high activities towards 
P. falciparum in vitro.3 In addition, the antimalarial activity of fosmidomycin (1) was demonstrated in 
several recent clinical Phase II trials.4-8  
The activity of these compounds is based on the inhibition of 1-deoxy-D-xylulose 4-phosphate 
reductoisomerase (DXR), the second enzyme in the non-mevalonate pathway. This enzyme mediates 
the conversion of 1-deoxy-D-xylulose 4-phosphate into 2C-methyl-D-erithrytol 4-phosphate.  
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Until now several X-ray crystallographic structures of DXR have been reported.9,10 Additionally, Silber 
et al. recently published a study of the AFMoC force field as an enhanced in silico predictor of the 
binding affinity of ligands to DXR.11 
Structural changes of fosmidomycin to enhance the activity of this lead towards P. falciparum, would 
provide critical information concerning structure-activity relationships of fosmidomycin. Much 
synthetic work has been dealing with phosphonate moiety alterations, such as ester prodrugs,12-14 
biphosphonates15 or carboxylic acids.16 Alternatively, several reports address hydroxamate moiety 
modifications, including benzoxazolone, benzothione, oxazopyridone or hydroxamic acid 
functionalities.17,18 Interestingly, variations affecting the three carbon spacer are scarce. An important 
strategy to gather more knowledge of the structure-activity relationships of fosmidomycin involves the 
restriction of the rotational freedom of this carbon chain. This approach could be realized by 
incorporating the C-1 and C-2 atoms in a three-membered ring. Here we present the synthesis and 
biological activity of such novel cyclopropyl analogues (3a-d, 4) of fosmidomycin. The synthetic 
strategy to generate the three-membered ring involves the intramolecular opening of an epoxide. This 
route was chosen above more obvious cyclopropanation schemes because it permits to employ readily 
available chiral epoxides for the synthesis of enantiomerically pure analogues. Moreover, even though 
the number of reports mentioning the catalytic enantioselective cyclopropanation of unsaturated 
phosphonates is growing, there is still no generally applicable highly enantioselective method to date. 
As it was envisioned that the use of a benzyl phosphonate would allow a clean final deprotection, 
dibenzylmethylphosphonate (7)19 was chosen as starting material (Scheme 1). Regioselective opening of 
epoxide 8 with 7 under Lewis acid conditions afforded alcohol 9. Special caution had to be taken to 
prevent side reactions, hence the temperature had to be monitored closely during the reaction. 
Deprotonation of alcohol 9 and subsequent elimination of the tosylate functionality yielded epoxide 5 as 
precursor for the formation of the three-membered ring. Ring closing was performed using a Lewis 
acid-assisted intramolecular epoxide ring opening, yielding alcohol 10. Unfortunately, during this step 
an unavoidable partial benzyl deprotection occurred, which was also observed in step a. In accordance 
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with literature data,20 the cyclopropane ring possessed the trans-configuration, which was proven via 1H 
NMR coupling constants. Next, alcohol 10 was converted into tosylate 11 using a mild but very 
effective procedure published by Yoshida et al.,21 which prevents further chlorine-assisted deprotection 
of the phosphonate. Subsequently, tosylate 11 was converted into Boc-benzyl protected hydroxylamine 
12, which, upon treatment with trifluoroacetic acid in dichloromethane, gave 13. Acylation of the 
benzyloxyamine moiety using different reagents yielded protected hydroxylamides 14a-d. Finally, 
hydrogenolysis of 14a-d afforded the free phosphonates 3a-d, which were purified via reversed phase 
HPLC. 
Application of the above-mentioned strategy starting from the dibenzylbenzylphosphonate22 led to the 
synthesis of the -phenyl substituted cyclopropane analogue 4 (Scheme 2). As opposed to the 
unsubstituted cyclopropane ring only the cis-adduct was formed, based on both 1H NMR coupling 
constants and a NOESY experiment. This result is in disagreement with a former study, which claims 
epoxide opening to yield exclusive formation of the trans-isomer irrespective of the -substituent.20  
The synthesized compounds were tested for inhibition of recombinant E. coli DXR because of the 
difficulties associated with the handling of the highly analogous P. falciparum enzyme. The conversion 
of DOXP to MEP by the enzyme was determined in an assay based on the NADPH dependency of the 
reaction.1 The results are summarized in Table 1. The initially synthesized racemic trans-cyclopropane 
3a displayed activity in the submicromolar range, which prompted us to prepare the enantiomerically 
pure (1R,2S)-analogue 3b. Compared to the racemic mixture this enantiomer displayed a remarkable 
activity enhancement, which indicates the preferred trans-cyclopropane stereochemistry to be (1R,2S). 
In fact, this eutomer represents the first synthesized analogue of fosmidomycin that exhibits similar 
activity on the DXR enzyme. Replacing the acetamide moiety of 3b by a formamide moiety (3c) caused 
an 8-fold increase of the IC50 value, while homologation to the propionamide (3d) reduced the binding 
affinity by a factor of more than 150. The racemic -phenyl-substituted cis-cyclopropane analogue 4 
had no significant binding activity towards the DXR-enzyme. Based on the observed activity in the 
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enzyme assay, compounds 3b and 3c were evaluated for their inhibitory effect against intra-erythrocytic 
forms of P. falciparum (strains Dd2 and 3D7) using a semi-automated microdilution assay as 
described.3 The growth of the parasites was monitored through the incorporation of tritium-labelled 
hypoxanthine. The results obtained are summarized in Table 2. 
The (1R,2S)-trans-cyclopropane 3b showed very promising in vitro antimalarial activity with both P. 
falciparum strains, performing equally as well as fosmidomycin. In accordance with the results obtained 
in the enzyme inhibition assay, the formamide analogue 3c showed a 5-fold decreased in vitro 
antimalarial activity. 
In summary a number of conformationally restricted fosmidomycin analogues have been synthesized. 
From this series, the (1R,2S)-trans-analogue with an N-hydroxy-N-acetamide group emerged as the best 
inhibitor of the E. coli DXR enzyme and proved equally as potent as fosmidomycin in inhibiting P. 
falciparum growth. 
 
Experimental Section 
General Methods and Materials. 
Melting points were determined on a Reichert Heizbank type 184321 melting point apparatus calibrated 
with acetanilide (mp 114.5 °C) or an Electrothermal AI9100 digital melting point apparatus and are 
uncorrected. The 1H, 13C and 31P NMR spectra were recorded in CDCl3, C6D6, MeOD or D2O on a 
Bruker Avance 300 MHz-spectrometer. Chemical shifts are in parts per million with respect to TMS. 
RP-LC spectra were recorded on a Agilent 1100 series LC/MS spectrometer with quaternary pump and 
DAD detector. Mass spectroscopy spectra were recorded on a single quadrupole spectrometer type VL. 
Optical rotations were measured on a Perkin Elmer 241 polarimeter. Silicagel (60Å, 0.063-0.200 mm) 
was purchased from BioSolve. Preparative reversed phase chromatography was performed on a 
Phenomenex Luna C-15 (2) 5 m particle (21.20 × 250 mm) column using 5 mM NH4OAc solution and 
MeCN as solvents. Enantiomeric excess calculation was performed on a Diacel Chiralcel OD-H column 
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using hexane and absolute EtOH as isocratic solvents (flow rate = 1 mL/min). Tetrahydrofuran was 
distilled from sodium on benzophenone; dichloromethane, pyridine and Et3N were distilled from CaH2 
unless otherwise stated. All other solvents and chemicals were used as purchased unless otherwise 
stated. n-BuLi was titrated from diphenylacetic acid prior to use. Reactions were performed under Ar-
atmosphere in oven-dried flasks unless otherwise stated.  
Dibenzyl 3-hydroxy-4-(p-toluenesulfonyloxy)butanephosphonate (9a). 
A 2.3 M solution of n-BuLi in hexanes (20.6 mL, 47.4 mmol) was added dropwise to a stirred solution 
of dibenzyl methylphosphonate (13.1 g, 47.4 mmol) in dry THF (94 mL) while the temperature was 
kept below -70°C. After 15 min of stirring a solution of glycidyl tosylate (7.2 g, 34.5 mmol) was added 
dropwise, followed by BF3.OEt2 (8.0 mL, 63.2 mmol) under continuous monitoring of temperature 
below -70°C. The mixture was stirred for 7 h at -78 °C, after which the reaction was quenched with a 
NH4Cl-solution (200 mL) and allowed to warm to room temperature. The aqueous phase was extracted 
three times with CH2Cl2 (200 mL). The combined organic fractions were dried on anhydrous MgSO4, 
the solids were filtered and solvents were removed under reduced pressure. The residual oil was purified 
via column chromatography (pentane/CH2Cl2/acetone: 6/3/1) giving 8.7 g of a thick grey-white oil in a 
yield of 50%. 
1H NMR (300.13 MHz, CDCl3) 1.57-1.97 (4H, m), 2.42 (3H, s), 3.77-3.92 (3H, m), 4.91 (1H, dd, J = 
11.9 and 8.4 Hz), 4.92 (1H, dd, J = 11.9 and 8.3 Hz), 5.01 (2H, dd, 11.9 and 9.2), 7.29-7.33 (12H, m), 
7.76 (2H, d, J = 8.3 Hz); 13C NMR (75.47 MHz, CDCl3) 21.6 (CH3), 21.9 (P-CH2, 1JPC = 142.2 Hz), 
25.8 (-CH2, 2JPC = 4.9 Hz), 67.4 (-OCH2, 2JPC = 6.0 Hz), 68.8 (-OCH, 3JPC = 13.2 Hz), 72.9 (-OCH2), 
128.0 (=CH), 128.5 (=CH), 128.6 (=CH), 129.9 (=CH), 132.7 (=CH), 136.2 (=C, 3JPC = 5.5 Hz), 145.0 
(=C); 31P NMR (121.50 MHz, CDCl3) 33.6; ESMS m/z 505 ([M]+H+). 
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Dibenzyl 3,4-epoxybutanephosphonate (5a). 
To a stirred solution of 9a (2.4 g, 4.76 mmol) in dry THF (35 mL) was added KOt-Bu (694 mg, 6.18 
mmol) in one portion at 0 °C and the mixture was stirred for 3 h at 0 °C. Saturated aqueous NH4Cl (80 
mL) was added and the mixture was allowed to warm to rt. The aqueous layer was extracted three times 
with CH2Cl2 (80 mL) and the combined organic fractions were dried on anhydrous MgSO4, filtered and 
the solvents were removed under reduced pressure. The resulting oil was purified via column 
chromatography (hexane/acetone: 3/2) yielding 1.17 g of a pale yellow oil (74%). 
1H NMR (300.13 MHz, CDCl3) 1.75-1.93 (4H, m), 2.41 (1H, dd, J = 4.8 and 2.6 Hz), 2.68-2.70 (1H, 
m), 2.90 (1H, ddt, J = 6.1, 4.1 and 2.3 Hz), 4.96 (1H, dd, J = 11.8 and 8.6 Hz), 4.96 (1H, dd, 11.8 and 
8.1 Hz), 5.05 (2H, dd, J = 11.8 and 9.0 Hz), 7.34 (10H, m); 13C NMR (75.47 MHz, CDCl3) 22.3 
(P-CH2, 1JPC = 142.7 Hz), 25.5 (-CH2, 2JPC = 4.4 Hz), 47.0 (-OCH2), 51.7 (-OCH, 3JPC = 19.8 Hz), 67.2 
(-OCH2, 2JPC = 6.6 Hz), 67.3 (-OCH2, 2JPC = 6.5 Hz), 128.0 (=CH), 128.5 (=CH), 128.7 (=CH), 136.3 
(=C, 3JPC = 6.0 Hz); 31P NMR (121.50 MHz, CDCl3) 32.2; ESMS m/z 333 ([M]+H+), 355([M]+Na+), 
687 ([2M]+Na+). 
Dibenzyl 2-(hydroxymethyl)-1-cyclopropylphosphonate (10a). 
A 2.4 M solution of n-BuLi in hexanes (5.11 mL, 12.3 mmol) was added dropwise to a stirred solution 
of 5a (3.4 g, 10.2 mmol) in dry THF at -78 °C. After 5 min of stirring BF3.OEt2 (2.58 mL, 20.5 mmol) 
was added dropwise, after which the mixture was stirred for 15 min at -78 °C. The reaction was 
quenched with saturated aqueous NH4Cl (250 mL) and the aqueous phase was extracted twice with 
CH2Cl2 (250 mL) and twice with CHCl3 (250 mL). The combined organic fractions were dried on 
anhydrous MgSO4, filtered and evaporated under reduced pressure. The residual oil was purified via 
column chromatography (hexane/CH2Cl2/acetone: 2/9/9), giving 1.56 g of a thick colorless oil (46%).  
1H NMR (C6D6, 300.13 MHz) 0.46 (1H, dddd, J = 11.6, 9.2, 5.7 and 4.4 Hz), 0.74 (1H, dddd, J = 9.2, 
5.5, 5.5 and 5.2 Hz), 1.10 (1H, dddd, J = 17.7, 8.4, 5.9 and 4.4 Hz), 1.69 (dddddd, J = 16.0, 8.4, 6.4, 5.4, 
5.4 and 5.4 Hz), 1.79 (1H, br s), 3.03 (1H, dd, J = 11.5 and 6.5 Hz), 3.35 (1H, ddd, J = 11.5, 5.4 and 2.0 
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Hz), 4.89 (1H, dd, J = 11.8 and 8.5 Hz), 4.95 (1H, dd, J = 11.8 and 8.5 Hz), 4.96 (1H, dd, J = 11.9 and 
8.5 Hz), 5.04 (1H, dd, J = 12.2 and 8.5 Hz), 7.00-7.27 (10H, m); 13C NMR (75.47 MHz, C6D6) 8.3 
(-CH2, 2JPC = 5.5 Hz), 9.4 (P-CH, 1JPC = 195.9 Hz), 19.7 (-CH, 2JPC = 4.4 Hz), 64.8 (-OCH2, 3JPC = 3.8 
Hz), 67.6 (-OCH2, 2JPC = 6.1 Hz), 67.7 (-OCH2, 2JPC = 6.5 Hz), 128.1 (=CH), 128.6 (=CH), 128.8 
(=CH), 136.6 (=C); 31P NMR (121.50 MHz, C6D6) 45.1; ESMS m/z 333 ([M]+H+), 665 ([2M]+H+), 
687 ([2M]+Na+). 
Dibenzyl 2-(p-toluenesulfonyloxymethyl)-1-cyclopropylphosphonate (11a). 
To a solution of alcohol 10a (380 mg, 1.143 mmol) in dry CH2Cl2 (5 mL) at 0 °C was added dry Et3N 
(480 μL, 3.43 mmol) and Me3N.HCl (33 mg, 0.343 mmol). A suspension of TsCl (327 mg, 1.715 mmol) 
in dry CH2Cl2 was added at 0°C, and the mixture was stirred for 1 h at the same temperature. Saturated 
aqueous NH4Cl (70 mL) was added and the aqueous layer was extracted 3 times with CH2Cl2 (70 mL). 
The combined organic fractions were dried on anhydrous MgSO4, filtered and the solvents were 
removed under reduced pressure. The residual oil was purified via column chromatography 
(hexane/CH2Cl2/acetone: 3/1/1) yielding 450 mg of a viscous colorless oil (81%). 
1H NMR (300.13 MHz, CDCl3) 0.60-0.82 (2H, m), 0.96-1.08 (1H, m), 1.68 (1H, dddddd, J = 15.4, 
8.4, 6.9, 6.8, 5.4 and 5.4 Hz), 2.34 (3H, s), 3.67 (1H, dd, J = 10.5 and 7.0 Hz), 3.81 (1H, ddd, J = 10.6, 
6.7 and 1.6 Hz), 4.89 (2H, dd, J = 11.9 and 8.4 Hz), 4.95 (1H, dd, J = 11.4 and 8.4 Hz), 4.96 (1H, dd, J 
= 11.4 and 8.3 Hz), 7.22 (12H, m), 7.65 (2H, d, J = 8.3 Hz); 13C NMR (75.47 MHz, CDCl3) 8.7 (-CH2, 
2JPC = 4.9 Hz), 10.1 (P-CH, 1JPC = 195.9 Hz), 15.9 (-CH, 2JPC = 3.9 Hz), 21.6 (-CH3), 67.5 (-OCH2, 
2JPC = 6.1 Hz), 67.7 (-OCH2, 2JPC = 6.1 Hz), 72.1 (-OCH2, 3JPC = 4.0 Hz), 127.9 (=CH), 128.5 (=CH), 
128.6 (=CH), 129.9 (=CH), 133.0 (=C), 136.2 (=C, 3JPC = 6.1 Hz), 136.3 (=C, 3JPC = 6.0 Hz), 145.0 (S-
C=); 31P NMR (121.50 MHz, CDCl3) 29.0; ESMS m/z 487 ([M]+H+). 
Dibenzyl 2-[N-(benzyloxy),N-(t-butoxycarbonyl)aminomethyl]-cyclopropylphosphonate (12a). 
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NaH (47.3 mg, 0.987 mmol, 50% in mineral oil) was added to a solution of tert-butyl N-
(benzyloxy)carbamate (220 mg, 0.987 mmol) in anhydrous DMF (5 mL) and the mixture was stirred for 
30 min at rt. A solution of 11a (400 mg, 0.822 mmol) in dry DMF (5 mL) was added dropwise to the 
solution containing the deprotonated carbamate and the reation mixture was stirred for 3 h at 50 °C. The 
reaction was quenched with saturated aqueous NH4Cl (40 mL) and the water phase was extracted 3 
times with CH2Cl2 (40 mL). The combined organic fractions were dried on anhydrous MgSO4, filtered 
and the solvents were removed under reduced pressure. The residual oil was purified via column 
chromatography (hexane/CH2Cl2/acetone: 4/1/1) yielding 352 mg of compound 12a as a colorless oil 
(80%).  
1H NMR (300.13 MHz, CDCl3) 0.72-0.89 (2H, m), 1.10 (1H, dddd, J = 18.2, 8.5, 5.6 and 4.2 Hz), 
1.46 (9H, s), 1.73 (1H, dddddd, J = 15.7, 8.3, 6.9, 6.9, 5.5 and 5.5 Hz), 3.29 (2H, d, J = 6.7 Hz), 4.83 
(2H, s), 4.97 (2H, dd, J = 11.8 and 7.9 Hz), 5.03 (1H, dd, J = 11.9 and 8.3 Hz), 5.03 (1H, dd, J = 12.0 
and 7.9 Hz), 7.30-7.38 (15H, m); 13C NMR (75.47 MHz, CDCl3) 9.3 (-CH2, 2JPC = 4.9 Hz), 10.0 
(P-CH, 1JPC = 195.4 Hz), 15.6 (-CH, 2JPC = 3.8 Hz), 28.3 (-CH3), 52.8 (-NCH2, 3JPC = 4.8 Hz), 67.3 
(-OCH2, 2JPC = 6.0 Hz), 67.4 (-OCH2, 2JPC = 5.5 Hz), 77.2 (-OCH2), 81.6 (O-C), 127.8 (=CH), 127.9 
(=CH), 128.3 (=CH), 128.5 (=CH), 128.6 (=CH), 129.4 (=CH), 135.6 (=C), 136.5 (=C, 3JPC = 6.6 Hz), 
136.6 (=C, 3JPC = 6.6 Hz), 156.6 (N-C=O); 31P NMR (121.50 MHz, CDCl3) 30.7; ESMS m/z 438 
([M]-Boc+2H+), 538 ([M]+H+). 
Dibenzyl 2-[N-(benzyloxy)aminomethyl]-cyclopropylphosphonate (13a). 
TFA (2.58 mL, 33.6 mmol) was added dropwise to a solution of 12a (350 mg, 0.651 mmol) in dry 
CH2Cl2 (6 mL) at 0 °C and the mixture was stirred for 45 min at 0 °C. The mixture was transferred into 
a separation funnel and saturated aqueous NaHCO3 (40 mL) was added. The aqueous layer was 
extracted twice with CH2Cl2 (40 mL) and twice with CHCl3 (40 mL). The combined organic layers were 
dried on MgSO4, filtered and the solvents were removed under reduced pressure yielding 256 mg of 
pale yellow solid in a yield of 90%. 
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mp 40-41 °C; 1H NMR (300.13 MHz, CDCl3) 0.61-0.74 (2H, m), 1.04-1.15 (1H, m), 1.60 (1H, 
dddddd, J = 16.1, 8.4, 6.7, 6.7, 5.4 and 5.4 Hz); 2.66 (1H, dd, J = 13.2 and 6.8 Hz), 2.75 (1H, ddd, J = 
13.2, 6.7 and 1.7 Hz), 4.62 (2H, s), 4.94 (2H, dd, J = 11.8 and 8.1 Hz), 5.00 (1H, dd, J = 11.9 and 8.3 
Hz), 5.02 (1H, dd, J = 11.9 and 8.3 Hz), 7.21-7.31 (15H, m); 13C NMR (75.47 MHz, CDCl3) 9.3 
(-CH2, 2JPC = 5.5 Hz), 10.0 (P-CH, 1JPC = 196.0 Hz), 15.9 (-CH, 2JPC = 3.8 Hz), 55.3 (-NCH2, 3JPC = 3.8 
Hz), 67.3 (-OCH2, 2JPC = 6.0 Hz), 67.4 (-OCH2, 2JPC = 6.1 Hz), 76.3 (-OCH2), 127.8 (=CH), 128.3 
(=CH), 128.4 (=CH), 128.5 (=CH), 136.6 (=C, 3JPC = 6.1 Hz), 136.6 (=C, 3JPC = 6.1 Hz), 137.8 (=C); 
31P NMR (121.50 MHz, CDCl3) 31.1; ESMS m/z 438 ([M]+H+), 460 ([M]+Na+), 875 ([2M]+H+). 
Dibenzyl 2-[N-acetyl,N-(benzyloxy)aminomethyl]-cyclopropylphosphonate (14a). 
Amine 13a (256 mg, 0.586 mmol) was dissolved in dry pyridine (6 mL). Ac2O (615 μL, 6.51 mmol) 
was added dropwise and the mixture was stirred overnight at rt. The mixture was transferred to a 
separation funnel and a 1 M HCl-solution (70 mL) was added. The aqueous layer was extracted twice 
with CH2Cl2 (70 mL) and twice with CHCl3 (70 mL). The combined organic fractions were dried on 
anhydrous MgSO4, filtered and the solvents were removed on rotary evaporation. The residual oil was 
dissolved in CH2Cl2 (40 mL), saturated aqueous NaHCO3 (40 mL) was added, the layers were separated 
and the aqueous phase was extracted twice with CH2Cl2 (40 mL) and once with CHCl3 (40 mL). The 
combined organic layers were dried on anhydrous MgSO4, filtered and the solvents were removed under 
reduced pressure. The residual oil was purified via column chromatography (hexane/CH2Cl2/MeOH: 
50/48/2) giving 253 mg of a pale yellow oil in an overall yield of 90%.  
1H NMR (300.13 MHz, CDCl3) 0.81 (1H, dddd, J = 12.0, 9.4, 5.3, 4.3 Hz), 0.89-0.97 (1H, m), 1.11 
(1H, dddd, J = 18.2, 8.4, 5.7 and 4.4 Hz), 1.73 (1H, dddddd, J = 15.7, 8.4, 7.0, 6.8, 5.4 and 5.4 Hz), 2.00 
(3H, s), 3.47 (1H, dd, J = 14.9 and 7.4 Hz), 3.53 (1H, ddd, J = 14.9, 6.6 and 1.8 Hz), 4.79 (2H, s), 4.95 
(1H, dd, J = 12.1 and 7.7 Hz); 4.97 (1H, dd, J = 11.8 and 8.4 Hz), 5.02 (1H, dd, J = 11.8 and 8.4 Hz), 
5.03 (1H, dd, J = 12.3 and 8.4 Hz), 7.19-7.30 (15H, m); 13C NMR (75.47 MHz, CDCl3) 9.4 (-CH2, 
2JPC = 5.0 Hz), 10.4 (P-CH, 1JPC = 185.4 Hz), 15.8 (-CH, 2JPC = 3.8 Hz), 20.4 (-CH3), 50.0 (-NCH2), 
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67.3 (-OCH2, 2JPC = 6.0 Hz) 67.4 (-OCH2, 2JPC = 6.0 Hz), 76.9 (-OCH2), 127.7 (=CH), 127.8 (=CH), 
128.3 (=CH), 128.5 (=CH), 128.7 (=CH), 129.0 (=CH), 129.1 (=CH), 134.4 (=C), 136.5 (=C, 3JPC = 6.1 
Hz), 136.6 (=C, 3JPC = 6.6 Hz), 167.8 (N-C=O); 31P NMR (121.50 MHz, CDCl3) 30.5; ESMS m/z 480 
([M]+H+). 
2-[N-(acetyl),N-(hydroxy)aminomethyl]-cyclopropylphosphonic acid (3a). 
To a solution of 14a (253 mg, 0.528 mmol) in MeOH (5 mL) was added Pd/C (100 mg, 10%). The 
reaction was placed under H2 (1 atm) and was stirred overnight at rt. The mixture was filtered over 
celite and the celite was washed with portions of MeOH. The filtrate was evaporated under reduced 
pressure; the residual oil was dissolved in a minimal amount of water and lyophilised. The resulting 
solid was purified via reversed phase HPLC using a gradient elution of 5 mM NH4OAc solution to 
MeCN in 20 min. The appropriate fractions were lyophilised, giving 80 mg of an amber amorphous 
solid in a yield of 72%. 
mp 100-102 °C; 1H NMR (300.13 MHz, MeOD) 0.45 (1H, m), 0.57 (1H, m), 0.77 (1H, m), 1.27 (1H, 
m), 1.95 (3H, s), 3.14-3.21 (1H, m), 3.53 (1H, dd, J = 14.3 and 5.3 Hz); 13C NMR (75.47 MHz, MeOD) 
9.6 (-CH2, 2JPC = 5.1 Hz), 14.6 (-CH, 1JPC = 177.8 Hz), 15.8 (-CH, 2JPC = 6.1 Hz), 20.2 (-CH3), 52.7 (-
NCH2, 3JPC = 3.3 Hz), 173.6 (N-C=O); 31P NMR (121.50 MHz, D2O) 22.7; ESMS m/z 210 ([M]+H+). 
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TABLES 
Table 1. Inhibition of recombinant E. coli DXR  
Compound IC50 (M) 
Fosmidomycin 0.048 
FR900098 0.058 
3a 0.160 
3b 0.050 
3c 0.313 
3d > 3.0  
4 > 30 
 
Table 2. In vitro growth inhibition of the P. falciparum strains Dd2 and 3D7  
 
Compound 
 
IC50 (M)______ 
Dd2                                3D7 
 
 
Fosmidomycin 0.48                                 0.40  
FR900098 0.28                                 0.24  
3b 0.48                                 0.32  
3c 2.0                                   2.1  
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FIGURE LEGENDS 
Figure 1. Targeted fosmidomycin analogues and synthetic strategy 
Scheme 1. Synthesis of the unsubstituted trans-cyclopropyl fosmidomycin analogues 
Scheme 2. Synthesis of substituted cis-cyclopropyl fosmidomycin analogue 
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